225 related articles for article (PubMed ID: 26545264)
1. Statistical issues in trials of preexposure prophylaxis.
Dunn DT; Glidden DV
Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
[TBL] [Abstract][Full Text] [Related]
2. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
3. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
4. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
5. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
[TBL] [Abstract][Full Text] [Related]
6. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
Venter WD
Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
[TBL] [Abstract][Full Text] [Related]
7. The European preexposure prophylaxis revolution.
Cairns G; McCormack S; Molina JM
Curr Opin HIV AIDS; 2016 Jan; 11(1):74-9. PubMed ID: 26599164
[TBL] [Abstract][Full Text] [Related]
8. Promise and pitfalls of pre-exposure prophylaxis for female sex workers.
Cowan FM; Delany-Moretlwe S
Curr Opin HIV AIDS; 2016 Jan; 11(1):27-34. PubMed ID: 26633639
[TBL] [Abstract][Full Text] [Related]
9. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.
Mugo NR; Ngure K; Kiragu M; Irungu E; Kilonzo N
Curr Opin HIV AIDS; 2016 Jan; 11(1):80-6. PubMed ID: 26575147
[TBL] [Abstract][Full Text] [Related]
10. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.
Durand-Zaleski I; Mutuon P; Charreau I; Tremblay C; Rojas D; Pialoux G; Chidiac C; Capitant C; Spire B; Cotte L; Chas J; Meyer L; Molina JM;
AIDS; 2018 Jan; 32(1):95-102. PubMed ID: 29210777
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
[TBL] [Abstract][Full Text] [Related]
12. The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.
Elion R; Coleman M
Curr Opin HIV AIDS; 2016 Jan; 11(1):67-73. PubMed ID: 26599165
[TBL] [Abstract][Full Text] [Related]
13. Considerations regarding antiretroviral chemoprophylaxis in MSM.
Poynten IM; Zablotska I; Grulich AE
Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
[TBL] [Abstract][Full Text] [Related]
14. Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials.
Sugarman J
Curr Opin HIV AIDS; 2016 Jan; 11(1):109-15. PubMed ID: 26633642
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
Leech AA; Burgess JF; Sullivan M; Kuohung W; Horný M; Drainoni ML; Christiansen CL; Linas BP
AIDS; 2018 Nov; 32(18):2787-2798. PubMed ID: 30234602
[TBL] [Abstract][Full Text] [Related]
16. The role of healthcare providers in the roll out of preexposure prophylaxis.
Krakower DS; Mayer KH
Curr Opin HIV AIDS; 2016 Jan; 11(1):41-8. PubMed ID: 26417953
[TBL] [Abstract][Full Text] [Related]
17. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
[TBL] [Abstract][Full Text] [Related]
18. PrEP: why are we waiting?
Lancet HIV
Lancet HIV; 2015 Oct; 2(10):e401. PubMed ID: 26423641
[No Abstract] [Full Text] [Related]
19. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
Fonner VA; Dalglish SL; Kennedy CE; Baggaley R; O'Reilly KR; Koechlin FM; Rodolph M; Hodges-Mameletzis I; Grant RM
AIDS; 2016 Jul; 30(12):1973-83. PubMed ID: 27149090
[TBL] [Abstract][Full Text] [Related]
20. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
